Essex Woodlands Management, Inc. Long-Term Concentrated

CIK: 0001542339 · Show all filings

Period: Q1 2018 (← Previous) (Next →)

Filing Date: May 15, 2018

Total Value ($000): $456,952 (100.0% shares, 0.0% debt)

Holdings (9)

AXGN AXOGEN INC 29.6%

Value ($000) $135,456 Shares 3,711,111 Est. Cost $4.01 Unrealized +665.6%

— REVANCE THERAPEUTICS INC 25.9%

Value ($000) $118,335 Shares 3,842,047 Est. Cost $31.50 Unrealized —

— CORIUM 23.5%

Value ($000) $107,282 Shares 9,353,304 Est. Cost $7.77 Unrealized —

— ABIOMED INC 12.9%

Value ($000) $58,727 Shares 201,818 Est. Cost $21.56 Unrealized —

MNOV MEDICINOVA INC 2.6%

Value ($000) $11,961 Shares 1,170,370 Est. Cost $2.95 Unrealized +237.8%

— ENDOLOGIX INC 2.5%

Value ($000) $11,583 Shares 1,257,468 Est. Cost $18.00 Unrealized —

— PSIVIDA 2.3%

Value ($000) $10,500 Shares 8,606,324 Est. Cost $1.22 Unrealized —

— CATALYST 0.5%

Value ($000) $2,110 Shares 78,622 Est. Cost $4.80 Unrealized —

ACUR ACURA PHARMACEUTICALS INC 0.2%

Value ($000) $998 Shares 1,956,397 Est. Cost $3.40 Unrealized -83.1%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
AXGN	AXOGEN INC	3,711,111	$135,456	29.6%	$4.01	+665.6%	COM	05463X106
—	REVANCE THERAPEUTICS INC	3,842,047	$118,335	25.9%	$31.50	—	COM	761330109
—	CORIUM	9,353,304	$107,282	23.5%	$7.77	—	COM	21887L107
—	ABIOMED INC	201,818	$58,727	12.9%	$21.56	—	COM	003654100
MNOV	MEDICINOVA INC	1,170,370	$11,961	2.6%	$2.95	+237.8%	COM	58468P206
—	ENDOLOGIX INC	1,257,468	$11,583	2.5%	$18.00	—	COM	29266S106
—	PSIVIDA	8,606,324	$10,500	2.3%	$1.22	—	COM	74440J101
—	CATALYST	78,622	$2,110	0.5%	$4.80	—	COM	14888D109
ACUR	ACURA PHARMACEUTICALS INC	1,956,397	$998	0.2%	$3.40	-83.1%	COM	00509L802